Study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis as well as biological pathways that lead to these conditions.
Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.